Chemistry Wealth Management LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 73.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,515 shares of the company’s stock after purchasing an additional 6,562 shares during the period. Johnson & Johnson makes up approximately 0.8% of Chemistry Wealth Management LLC’s holdings, making the stock its 23rd largest holding. Chemistry Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,405,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of JNJ. Glassy Mountain Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $35,000. GW&K Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $35,000. Dark Forest Capital Management LP increased its position in shares of Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares in the last quarter. Retirement Financial Solutions LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $40,000. Finally, Ruedi Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $42,000. 67.57% of the stock is currently owned by institutional investors.
Johnson & Johnson Stock Down 0.2 %
Johnson & Johnson stock opened at $163.87 on Thursday. The company’s 50 day simple moving average is $160.72 and its 200 day simple moving average is $163.68. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The firm has a market capitalization of $425.85 billion, a price-to-earnings ratio of 34.28, a PEG ratio of 2.80 and a beta of 0.54. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd were paid a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 2.90%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend was Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 99.58%.
Insider Buying and Selling at Johnson & Johnson
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at $10,549,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.20% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on JNJ shares. StockNews.com started coverage on Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Morgan Stanley lifted their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 19th. UBS Group began coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective for the company. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Finally, Citigroup initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $171.57.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free research report on Johnson & Johnson from StockNews.com
- Smartsheet Investors’ Hasty Exit Can Be Your Gain
- Agilent Technologies Stock: Ready to Rise off the Floor
- Oilfield Services Growing Faster Than Wider Energy Sector
- La-Z-Boy Reclines To The Buy Zone As Industry Normalizes
- Five stocks we like better than Johnson & Johnson
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
